Trial: 201909052

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC# 776864) in addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

Phase

III

Principal Investigator

Thaker, Premal

Disease Site

Corpus Uteri

Learn more about this study at: clinicaltrials.gov